World J Diabetes. 2011 April 15; 2(4): 49-53.
Published online 2011 April 15. doi: 10.4239/wjd.v2.i4.49.
Age related changes in pancreatic beta cells: A putative extra-cerebral site of Alzheimer’s pathology
Magdalena Maj, Aysegul Ilhan, Dashurie Neziri, Wolfgang Gartner, Tord Berggard, Johannes Attems, Wolfgang Base and Ludwig Wagner.
Magdalena Maj, Aysegul Ilhan, Dashurie Neziri, Wolfgang Gartner, Wolfgang Base, Ludwig Wagner, Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, 1090 Vienna, Austria
Tord Berggard, Alligator Bioscience AB, SE-223 70 Lund, Scheelevägen 19, Sweden
Johannes Attems, Newcastle University, Institute for Ageing and Health, Newcastle upon Tyne, NE4 5PL, United Kingdom
Author contributions: Maj M, Berggard T, and Wagner L wrote this manuscript; Ilhan A and Neziri D were responsible for manuscript correction and discussion; Gartner W and Base W participated in manuscript correction and critical review; and Attems J was responsible for consultation and discussion.
Correspondence to: Ludwig Wagner, MD, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. ludwig.wagner@meduniwien.ac.at
Telephone: +43-1-40400-4319 Fax: +43-1-40400-7790
Received May 28, 2010; Revised March 29, 2011; Accepted April 5, 2011;
Abstract
Frequent concomitant manifestation of type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) has been recently demonstrated by epidemiological studies. This might be due to functional similarities between β-cells and neurons, such as secretion on demand of highly specific molecules in a tightly controlled fashion. An additional similarity represents the age-related alteration of hyperphosphorylated tau in AD patients. Similarly, alterations have been identified in β-cells of T2DM patients. The islet amyloid polypeptide has been associated with β-cell apoptosis. As a consequence of increasing age, the accumulation of highly modified proteins together with decreased regenerative potential might lead to increasing rates of apoptosis. Moreover, reduction of β-cell replication capabilities results in reduction of β-cell mass in mammals, simultaneously with impaired glucose tolerance. The new challenge is to learn much more about age-related protein modifications. This can lead to new treatment strategies for reducing the incidence of T2DM and AD.
Keywords: Type 2 diabetes mellitus, Pancreatic beta cells, Age, Alzheimer’s disease, Hyperphosphorylated tau, Islet amyloid polypeptide
INTRODUCTION
Prevalence of impaired glucose tolerance and type 2 diabetes mellitus (T2DM) is increasing among the elderly in humans. The absolute number of T2DM patients is rising worldwide, particularly in industrialized countries. This is not only because of the higher incidence of obesity and reduced physical exercise, but is also due to the longer life expectancy in these countries, as well as superior food quality, and the availability of highly effective medication. However, a longer life span brings with it age-associated diseases such as diabetes mellitus type 2, cognitive disorders, and Alzheimer’s disease (AD). Primarily, one would not expect that these two very different forms of age related complications (TD2M and AD) to have any connection. Yet, epidemiological studies have demonstrated that, when compared with age matched individuals with absence of cognitive dysfunction[1,2] , impaired glucose tolerance and T2DM is more prevalent among AD patients. The link between these entities with different loci of pathological processes might be found in similar key mediators or signaling pathways. In both, the pancreatic beta cell and neurons of the central nervous system, secretion on demand of highly specific molecules represents a genuine task. This is mediated via a tightly controlled exocytosis process. The SNARE (soluble N-ethylmaleimide-sensitive-factor attachment protein receptor) protein complex gears transmitter and insulin secretion at neurons and beta cells, respectively. The SNARE complex exerts its function at the neuronal synapse and in the β-cell, using already pre-primed mature granules. Three so called SNARE proteins participate in fusing the vesicles to the plasma membrane: the vesicle-associated membrane protein (VAMP, also called synaptobrevin); syntaxin, an integral plasma membrane protein; and the synaptosomal-associated protein of 25 kDa (SNAP-25), anchored to the plasma membrane via a palmitoyl group. Together, these three proteins form a helical bundle consisting of four amphipathic helices, or SNARE motifs, two of which are contributed by SNAP-25[3]. It is believed that assembly of the SNARE complex proceeds in a zipper-like fashion from the N-terminal end of the interacting helices toward the C-terminal membrane anchors. In this way, assembly of the proteins in the opposing membranes pulls the membranes together[4]. At the beginning of membrane fusion, the SNARE proteins are located in still separated membranes (so-called trans-complexes) and, after fusion, the trans-membrane segments of the SNAREs are present in the same membrane (cis-complexes). To restore the cell for new exocytosis events, the cis-complexes are then disassembled by NSF (N-ethylmaleimide-sensitive factor) and additional cofactors[5], and vesicles containing VAMP are recycled. Secretagogin, a novel hexa EF-hand calcium-binding protein was recently found to interact with SNAP-25[6]. Further complex interdependencies will be demonstrated in establishing inter-actoms[7].
ALZHEIMER’S PATHOLOGY IN PANCREATIC β-CELLS
As most cellular processes are regulated by multi-protein complexes, abolishing or enhancing a protein-protein interaction may have a profound impact and possibly manifests in distinct diseases. Since protein-protein interactions are critical events for a wide range of physiological and pathological processes, the precise control of these interactions and their biological consequences present a major challenge and opportunity for modern drug design[8]. Hyperphosphorylation and glycosylation might induce impairment of the protein interaction machinery. As protein expression deficiencies of SNARE members have been demonstrated in the brain at the Lewy body variant of AD patients[9], there might exist forms of T2DM in which pancreatic β-cells undergo similar expression deficiencies, but this is still a matter of investigation.
In contrast to neuronal transmitters, insulin does not undergo a reuptake into β-cells. The premature insulin granules[10] have to be transported to the cell periphery along microtubules via an energy-consuming process using kinesin[11]. In this respect, microtubular dynamics as well as microtubule-associated protein tau (MAPT), also named tau, play an important role. Abnormalities in tau protein structure such as tangles and hyperphosphorylated tau aggregates were identified in the brains of AD patients[12,13] about 30 years ago. This has led to the technical term tauopathy and has been defined as detergent insoluble tau aggregates forming tangels and neuritic plaques[14]. Very recently, hyperphosphorylated tau, representing a factor responsible for the inhibition of microtubule assembly and microtubule disruption[15], has been identified in pancreatic islets of Langerhans of T2DM patients[16]. In contrast, this was not found in pancreatic islets of healthy individuals. Such data have been confirmed by in vitro studies using insulinoma tissue and cell lines from rodents[17]. At least six individual tau isoforms have been identified in these rodent β-cell lines, of which two are of higher molecular weight than the brain derived isoforms. Insoluble aggregates were isolated and demonstrated. Most interestingly, a slight but not significant up-regulation of tau[18] expression could be defined at the gene level using expression screens when comparing normal age matched donor islets with pancreatic islets from T2DM patients.
Although tau has become an important molecule in defining AD pathology, it is not solely responsible for disease development[19]. In the brain, extracellular beta amyloid deposits are the second main hallmark of AD pathology. Interestingly, a homologous protein[20] named islet amyloid polypeptide (IAPP)[21] is present in beta cells, which is intriguing in this respect. It is co-expressed and secreted with insulin by pancreatic beta cells[22,23]. The IAPP has a propensity to misfold and aggregate into cytotoxic oligomers, which result in islet amyloid deposits found in T2DM patients[24]. Oligomers of human IAPP are known to cause membrane disruption[25], and are therefore involved in the mediation of β-cell apoptosis in T2DM. Interestingly, the single amino acid mutation (proline substitution) in rodent IAPP hinders the formation of IAPP deposits[22], and rodents do not spontaneously develop diabetes characterized by islet amyloid deposits[26]. This, in turn, has led to the development of transgenic rats expressing the human variant of IAPP[27]. The transgenic rat model indeed resembles the T2DM of humans closely, and provides proof that this molecule is involved in derangement of β-cell function. It is of note that, using these models, it has been shown that the toxic effect of human IAPP on β-cell apoptosis is initiated by a threshold-dependent effect[26].
MODIFICATIONS OF INSULIN SECRETION
Insulin secretion from pancreatic beta cells has been monitored in a pulsatile mode under physiological conditions[28,29]. The frequency of pulses changes depending on the blood glucose level, and can be influenced by drugs such as sulfonylurea[29]. Most interestingly, impairment of this mode of secretion has been observed much earlier than the abnormal glucose tolerance could be measured[30]. Each pulse of insulin release is preceded by an increase of intracellular calcium[29]. This tightly controlled mechanism as reviewed by Tengholm and Gylfe[31] is deranged in individuals with impaired glucose tolerance and diabetes[32,33]. Additionally, an age-dependent change in pulsatile insulin secretion has been demonstrated in animal models[34] as well as in humans[35].
β-CELL REPLICATION AND AGE
It has been demonstrated in rodent models that the beta cell mass is the result of a balanced mode of replication and apoptosis[36,37]. An adjusted increase in replication has been found in obesity of rodents[38] and humans[39]. Moreover, the adaptive increase in beta cell mass has been shown to have important biological relevance for the increased insulin demand in pregnancy[40,41,42]. Furthermore, as depicted in rats, these adaptations are necessary to balance the age-related insulin resistance building up within 12 mo of birth[34]. Data beyond this age are not available from rats, though it has to be speculated that this β-cell replicative potential decreases in rodents in an age-dependent manner[43] as it has been shown for humans[44]. In younger individuals, β-cell mass can adapt to increase in body mass in order to maintain glucose tolerance within the normal range, this seems not to be the case in older individuals.
β-CELL APOPTOSIS AND AGE
Although T2DM has been associated with increased β-cell apoptosis[44,45,46], it does not necessarily mean that there is an increase in apoptosis going along with the age. However, there exists clear evidence that islet amyloid polypeptide increases with age at the islet of Langerhans[47,48]. This physiological peptide can cause apoptosis in its oligomeric form[25,45,49,50]. In addition to this, hyperphosphorylated tau protein can accumulate within the islet of Langerhans, as mentioned above[16]. Rodent models suggest that increased apoptosis might be responsible for the decrease in β-cell mass[26,27,51,52].
PROTECTIVE EFFECTS
It has been suggested that several protective effects exist to prevent neuronal death[53,54]. The former author describes that the calcium-binding protein secretagogin might exhibit a neuro-protective effect. This protein is highly expressed at the pancreatic islet of Langerhans, and might indeed exert important sensing capabilities at the calcium spikes preceding each pulse of insulin secretion[55]. Some preliminary data have been suggested in recent work, which might indicate that this protein provides more resistance to β-cell stressors under in vitro conditions[17]. Similarly, chaperon proteins have been implicated in refolding proteins back into their normal structure, following derangement from their native structure due to exposure to toxins or disease-mediated changes in body temperature[56,57].
Further basic research work will be necessary to teach us how age-related changes in β-cells can be reduced, prevented and counteracted.
Footnotes
Supported by the Grant from the National Bank of Austria, No. 13402, and the Fund of the Major of the City of Vienna, No. 08052
Peer reviewers: Moshira Abdel Hakim Rateb, MD, Assistant Professor of Human Physiology, Faculty of Medicine (Kasr Al Aini.), Manial El Roda, Cairo University, Cairo, Egypt
S- Editor Zhang HN L- Editor Herholdt A E- Editor Zhang L
References
1.
Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53:474-481.
2.
Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med. 2004;82:510-529.
3.
Sutton RB, Fasshauer D, Jahn R, Brunger AT. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature. 1998;395:347-353.
4.
Lin RC, Scheller RH. Structural organization of the synaptic exocytosis core complex. Neuron. 1997;19:1087-1094.
5.
Sollner T, Bennett MK, Whiteheart SW, Scheller RH, Rothman JE. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell. 1993;75:409-418.
6.
Rogstam A, Linse S, Lindqvist A, James P, Wagner L, Berggard T. Binding of calcium ions and SNAP-25 to the hexa EF-hand protein secretagogin. Biochem J. 2007;401:353-363.
7.
Bauer MC, O’Connel DJ, Maj M, Wagner L, Wagner L, Cahill DJ, Linse S. Identification of a high-affinity network of secretagogin-binding proteins involved in vesicle secretion. Molecular BioSystems, in process. .
8.
Toogood PL. Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem. 2002;45:1543-1558.
9.
Mukaetova-Ladinska EB, Xuereb JH, Garcia-Sierra F, Hurt J, Gertz HJ, Hills R, Brayne C, Huppert FA, Paykel ES, McGee MA. Lewy body variant of Alzheimer’s disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe. ScientificWorldJournal. 2009;9:1463-1475.
10.
Orci L, Ravazzola M, Amherdt M, Madsen O, Vassalli JD, Perrelet A. Direct identification of prohormone conversion site in insulin-secreting cells. Cell. 1985;42:671-681.
11.
Varadi A, Tsuboi T, Johnson-Cadwell LI, Allan VJ, Rutter GA. Kinesin I and cytoplasmic dynein orchestrate glucose-stimulated insulin-containing vesicle movements in clonal MIN6 beta-cells. Biochem Biophys Res Commun. 2003;311:272-282.
12.
Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084-6089.
13.
Ihara Y, Nukina N, Miura R, Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer’s disease. J Biochem. 1986;99:1807-1810.
14.
Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:95-130.
15.
Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci USA. 2006;103:8864-8869.
16.
Miklossy J, Qing H, Radenovic A, Kis A, Vileno B, Laszlo F, Miller L, Martins RN, Waeber G, Mooser V. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging. 2010;31:1503-1515.
17.
Maj M, Gartner W, Ilhan A, Neziri D, Attems J, Wagner L. Expression of TAU in insulin-secreting cells and its interaction with the calcium-binding protein secretagogin. J Endocrinol. 2010;205:25-36.
18.
Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, Tseng YH, Roberson RS, Ricordi C, O’Connell PJ, Gonzalez FJ. Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell. 2005;122:337-349.
19.
Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329-344.
20.
Yan LM, Velkova A, Tatarek-Nossol M, Andreetto E, Kapurniotu A. IAPP mimic blocks Abeta cytotoxic self-assembly: cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer’s disease and type II diabetes. Angew Chem Int Ed Engl. 2007;46:1246-1252.
21.
Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 1987;84:8628-8632.
22.
Gurlo T, Ryazantsev S, Huang CJ, Yeh MW, Reber HA, Hines OJ, O’Brien TD, Glabe CG, Butler PC. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol. 2010;176:861-869.
23.
Young AA, Gedulin B, Wolfe-Lopez D, Greene HE, Rink TJ, Cooper GJ. Amylin and insulin in rat soleus muscle: dose responses for cosecreted noncompetitive antagonists. Am J Physiol. 1992;263:E274-E281.
24.
Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes. 1999;48:241-253.
25.
Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes. 2007;56:65-71.
26.
Matveyenko AV, Butler PC. Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. ILAR J. 2006;47:225-233.
27.
Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes. 2004;53:1509-1516.
28.
Bergsten P. Glucose-induced pulsatile insulin release from single islets at stable and oscillatory cytoplasmic Ca2+. Am J Physiol. 1998;274:E796-E800.
29.
Gilon P, Shepherd RM, Henquin JC. Oscillations of secretion driven by oscillations of cytoplasmic Ca2+ as evidences in single pancreatic islets. J Biol Chem. 1993;268:22265-22268.
30.
Schmitz O, Porksen N, Nyholm B, Skjaerbaek C, Butler PC, Veldhuis JD, Pincus SM. Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. Am J Physiol. 1997;272:E218-E226.
31.
Tengholm A, Gylfe E. Oscillatory control of insulin secretion. Mol Cell Endocrinol. 2009;297:58-72.
32.
Lang DA, Matthews DR, Burnett M, Turner RC. Brief, irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man. Diabetes. 1981;30:435-439.
33.
O’Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med. 1988;318:1225-1230.
34.
Matveyenko AV, Veldhuis JD, Butler PC. Adaptations in pulsatile insulin secretion, hepatic insulin clearance, and beta-cell mass to age-related insulin resistance in rats. Am J Physiol Endocrinol Metab. 2008;295:E832-E841.
35.
Ihm SH, Matsumoto I, Sawada T, Nakano M, Zhang HJ, Ansite JD, Sutherland DE, Hering BJ. Effect of donor age on function of isolated human islets. Diabetes. 2006;55:1361-1368.
36.
Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes. 1995;44:249-256.
37.
Lee YC, Nielsen JH. Regulation of beta cell replication. Mol Cell Endocrinol. 2009;297:18-27.
38.
Flier SN, Kulkarni RN, Kahn CR. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proc Natl Acad Sci USA. 2001;98:7475-7480.
39.
Flatt PR, Green BD. Nutrient regulation of pancreatic beta-cell function in diabetes: problems and potential solutions. Biochem Soc Trans. 2006;34:774-778.
40.
Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, Fontaine M, Yen MH, Kim SK. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science. 2007;318:806-809.
41.
Parsons JA, Brelje TC, Sorenson RL. Adaptation of islets of Langerhans to pregnancy: increased islet cell proliferation and insulin secretion correlates with the onset of placental lactogen secretion. Endocrinology. 1992;130:1459-1466.
42.
Van Assche FA, Aerts L, De Prins F. A morphological study of the endocrine pancreas in human pregnancy. Br J Obstet Gynaecol. 1978;85:818-820.
43.
Perfetti R, Wang Y, Shuldiner AR, Egan JM. Molecular investigation of age-related changes in mouse endocrine pancreas. J Gerontol A Biol Sci Med Sci. 1996;51:B331-B336.
44.
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.
45.
Meier JJ, Kayed R, Lin CY, Gurlo T, Haataja L, Jayasinghe S, Langen R, Glabe CG, Butler PC. Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. Am J Physiol Endocrinol Metab. 2006;291:E1317-E1324.
46.
Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death?. Science. 2005;307:380-384.
47.
Leckström A, Lundquist I, Ma Z, Westermark P. Islet amyloid polypeptide and insulin relationship in a longitudinal study of the genetically obese (ob/ob) mouse. Pancreas. 1999;18:266-273.
48.
Takada K, Kanatsuka A, Tokuyama Y, Yagui K, Nishimura M, Saito Y, Makino H. Islet amyloid polypeptide/amylin contents in pancreas change with increasing age in genetically obese and diabetic mice. Diabetes Res Clin Pract. 1996;33:153-158.
49.
Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev. 2008;29:303-316.
50.
Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature. 1994;368:756-760.
51.
Butler AE, Janson J, Soeller WC, Butler PC. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes. 2003;52:2304-2314.
52.
Stefan M, Simmons RA, Bertera S, Trucco MM, Esni F, Drain P, Nicholls RD. Global deficits in development, function, and gene expression in the endocrine pancreas in a deletion mouse model of Prader-Willi syndrome. Am J Physiol Endocrinol Metab. 2011;epub ahead of print.
53.
Attems J, Preusser M, Grosinger-Quass M, Wagner L, Lintner F, Jellinger K. Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer’s disease. Neuropathol Appl Neurobiol. 2008;34:23-32.
54.
Attems J, Quass M, Gartner W, Nabokikh A, Wagner L, Steurer S, Arbes S, Lintner F, Jellinger K. Immunoreactivity of calcium binding protein secretagogin in the human hippocampus is restricted to pyramidal neurons. Exp Gerontol. 2007;42:215-222.
55.
Wagner L, Oliyarnyk O, Gartner W, Nowotny P, Groeger M, Kaserer K, Waldhausl W, Pasternack MS. Cloning and expression of secretagogin, a novel neuroendocrine- and pancreatic islet of Langerhans-specific Ca2+-binding protein. J Biol Chem. 2000;275:24740-24751.
56.
Vabulas RM, Raychaudhuri S, Hayer-Hartl M, Hartl FU. Protein folding in the cytoplasm and the heat shock response. Cold Spring Harb Perspect Biol. 2010;2:a004390.
57.
Zhang H, Xu LQ, Perrett S. Studying the effects of chaperones on amyloid fibril formation. Methods. 2011;53:285-294.